Fluralaner
Fluralaner (INN) is a systemic insecticide and acaricide that is administered orally or topically. The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014 and Bravecto Plus as a topical treatment for cats in November 2019, with warnings about possible side effects in both species. The EU approved the drug in February 2014. Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015. For treating mites in chickens, a solution for use in drinking water is available under the name Exzolt; it was introduced by the EU in 2017.
Clinical data | |
---|---|
Pronunciation | /ˌflʊərəˈlænər/ FLOOR-ə-LAN-ər |
Trade names | Bravecto, Exzolt |
Other names |
|
License data |
|
Routes of administration | By mouth |
ATCvet code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 20–27%; reduced in the fasted state |
Elimination half-life | 9.3–16.2 days |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.215.812 |
Chemical and physical data | |
Formula | C22H17Cl2F6N3O3 |
Molar mass | 556.29 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
SMILES
| |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.